DPP-4 inhibitors in clinical practice.

Postgraduate Medicine
Anna I PalalauA H Barnett

Abstract

Type 2 diabetes is a very common worldwide disorder, with major consequences for patients, society, and health care services. Good glycemic control is an important aspect of diabetes management because it has a significant impact on diabetes-related microvascular and possibly macrovascular complications. Based on our understanding of the pathogenesis of diabetes, multiple pharmacological interventions have been developed in the past 60 years. Although effective, none have had a lasting effect on glycemic control because of the progressive nature of type 2 diabetes requiring combination therapies and insulin treatment. In addition, several pharmacologic interventions have undesirable side effects, including hypoglycemia and weight gain. Drugs targeting the incretin pathway are the latest addition to the available antidiabetes agents. Incretin-based therapy is either delivered orally (dipeptidyl peptidase-4 [DPP-4]) inhibitors or injected subcutaneously (glucagon-like peptide-1 [GLP-1] mimetics and analogues). Dipeptidyl peptidase-4 inhibitors are effective either as a single or combination therapy in lowering glycated hemoglobin, fasting and postprandial glucose levels, with a low incidence of hypoglycemia and no weight gain. Th...Continue Reading

References

May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D J DruckerJ F Habener
Nov 1, 1988·The Journal of Clinical Endocrinology and Metabolism·M ChenD Porte
Feb 1, 1988·The Journal of Clinical Investigation·K S PolonskyE Van Cauter
Aug 1, 1986·The Journal of Clinical Endocrinology and Metabolism·M A NauckW Creutzfeldt
Nov 1, 1973·The Journal of Clinical Endocrinology and Metabolism·J DupreJ C Brown
Mar 24, 1998·Annual Review of Medicine·L J Goodyear, B B Kahn
Apr 13, 1999·JAMA : the Journal of the American Medical Association·C Marwick
Feb 9, 2000·Life Sciences·R G Yip, M M Wolfe
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·F S FacchiniG M Reaven
Jul 24, 2002·Diabetologia·A LieblUNKNOWN ODE-2 Advisory Board
Sep 17, 2003·Current Diabetes Reports·Bo Ahrén
Oct 1, 1964·The Journal of Clinical Endocrinology and Metabolism·H ELRICKY ARAI
Aug 5, 2004·The Journal of Clinical Endocrinology and Metabolism·Rebecca L HullSteven E Kahn
Apr 13, 2005·Lancet·Michael StumvollTimon W van Haeften
Apr 22, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·I Barroso
Jun 9, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·UNKNOWN IDF Clinical Guidelines Task Force
Jul 11, 2006·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·R E PratleyD Holmes
Nov 1, 2006·International Journal of Clinical Practice·A Barnett

❮ Previous
Next ❯

Citations

Dec 1, 2011·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Abd A Tahrani, Anthony H Barnett
Mar 28, 2012·Arhiv za higijenu rada i toksikologiju·Lara Batičić PučarJadranka Varljen
Jan 10, 2014·Applied Biochemistry and Biotechnology·Margarita Juárez-MontielLourdes Villa-Tanaca
Jul 22, 2014·BioMed Research International·Genovefa D KolovouSophie Mavrogeni
Oct 26, 2011·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Aug 2, 2011·Clinical Therapeutics·Deanna S KaniaZachary A Weber
Jul 2, 2016·Indian Journal of Endocrinology and Metabolism·Manash P BaruahMurchana Barkakati
Jun 25, 2016·Nature Reviews. Endocrinology·Abd A TahraniClifford J Bailey
Jul 15, 2015·Chemical Society Reviews·Tegan P Stockdale, Craig M Williams
May 21, 2015·World Journal of Experimental Medicine·Hiroyuki KonyaMitsuyoshi Namba
Nov 24, 2011·Diabetes & Metabolism Journal·Hyun Jeong Jeon, Tae Keun Oh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.